Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06063213 · ClinicalTrials.gov registry record
Using Transcriptional Assessment of Immune Response to Assess Immunosuppression After Liver Transplantation
A clinical trial of Transplant Complication, sponsored by University of Florida.
- Active
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT06063213 is a study of Transplant Complication that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06063213, a study of Transplant Complication, is active but no longer recruiting, sponsored by University of Florida.
- ACTIVE NOT RECRUITING
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
To develop a prospective quantitative liver allograft monitoring protocol and retrospectively validate the use of Phenotypic personalized medicine (PPM) in immunosuppression dosing in liver transplant recipients.
Conditions Studied
Study Locations (1)
Florida
- University of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-12-15 |
| Est. Completion | 2026-10-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06063213
The ClinicalTrials.gov registry entry for NCT06063213 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transplant Complication appearing as the primary indexed condition, and to 0 interventions.
NCT06063213 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06063213 about?
NCT06063213 is a clinical study titled "Using Transcriptional Assessment of Immune Response to Assess Immunosuppression After Liver Transplantation". To develop a prospective quantitative liver allograft monitoring protocol and retrospectively validate the use of Phenotypic personalized medicine (PPM) in immunosuppression dosing in liver transplant recipients.
What is the current status of trial NCT06063213?
This trial is currently active not recruiting. The enrollment target is 40 participants. The study started on 2023-12-15. Estimated completion is 2026-10-15.
What conditions does trial NCT06063213 study?
This clinical trial studies the following conditions: Transplant Complication.
Who is sponsoring clinical trial NCT06063213?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06063213 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transplant Complication
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.